Drug Profile
Research programme: TRPA1 protein inhibitors - Ario Pharma
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator PharmEste
- Developer Ario Pharma
- Class Small molecules
- Mechanism of Action TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Asthma in United Kingdom (PO)
- 11 Sep 2014 Research programme: TRPA1 protein inhibitors - Ario Pharma is available for licensing as of 11 Sep 2014. http://www.ariopharma.com/
- 11 Sep 2014 Preclinical trials in Asthma in United Kingdom (PO)